PatientsPrivate

Patients

Thank you for choosing to take part in the iFraP trial. Here we have included information about the iFraP resources that we hope you find helpful.

Please also look out for your follow up questionnaires 2 weeks and 3 months after your Fracture Liaison Service appointment. These will arrive by post or email depending on your preference. Your replies are really important to us!

In your Fracture Liaison Service appointment, the healthcare professional might have used the iFraP Treatment Discussion Aid.

You should also have a copy of your Bone Health Record. This document provides you with a summary of what was discussed during the appointment.

Do you want to learn more about the iFraP Bone Health Record?

Watch this video to learn more about your Bone Health Record and also see the iFraP Treatment Discussion Aid tool which was used to develop it:

Do you have questions about the iFraP Treatment Discussion Aid?

You may be wondering:

How does the iFraP Treatment Discussion Aid know what is recommended for me?
How does the iFraP Treatment Discussion Aid know what my risk of breaking a bone is?
How is fracture risk calculated or estimated?
How does the clinician/iFraP Treatment Discussion Aid decide whether/which drugs to discuss with me?
What do the ticks mean in the drug information section?
Where does the evidence on benefits and possible side effects come from?
How sure are we that the information is accurate?

Watch this video that answers some Frequently Asked Questions about the iFraP Treatment Discussion Aid:

iFraP tool Terms of Reference, funding and conflicts of interest statement

The clinical advice given in the iFraP tool is a guide, informed by national clinical osteoporosis guidelines (National Osteoporosis Guideline Group and Scottish Intercollegiate Guideline) and clinical judgement should prevail.

Evidence on drug benefits and side effects is derived from relevant NICE guidelines and drug specific Summary of Product Characteristics. Where no data exists, assumptions have been made based on data from other similar drugs and other sources of evidence e.g. meta-analyses and verified by external scientific advisors. Uncertainty is expressed by the use of the word ‘about’. Fracture risk, (if not manually entered) is estimated from look up tables, derived from FRAX and based on age, gender, steroid use, presence of osteoporosis and prior fracture, assuming a normal BMI (25).

This tool was developed by a team led by Dr Zoe Paskins and funded by the Royal Osteoporosis Society, the Haywood Foundation and the National Institute for Health Research (NIHR) [Clinician Scientist Award (CS-2018-18-ST2-010)/NIHR Academy]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Neither Dr Paskins nor the funders serve to gain or lose from decisions clinicians or patients make when using the iFraP tool.

Tool last updated 24th August 2022